Diagonal Bio appoints new CFO
Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) has appointed Fata Mrsic as the new Chief Financial Officer (CFO). Fata will assume the position on June 14, 2024, and be part of the Management Team.
Fata Mrsic has extensive financial and accounting experience. She has held Business Controller and Accounting positions at several companies in the past 15 years, some with global presence. Fata has a Diploma in Business Controlling from the University of Lund.
“We welcome Fata Mrsic as our new CFO. Fata knows our company well already since she started as Business Controller in Diagonal Bio in March this year. Her vast experience within the field will contribute highly to the operational and strategic work at Diagonal Bio,” comments Karin Wehlin, CEO at Diagonal Bio.
“I am happy to continue my journey within Diagonal Bio. Our innovative way to speed up the testing process for different viruses and to contribute to better health in animals and humans is something that I am very passionate about. It’s an exciting time to be part of the company, now that we have LAMPlify®️ in Pilot tests at veterinarians. I look forward to our journey,” says Fata Mrsic.
For more information about the Company, please contact:
Karin Wehlin, CEO
Phone: +46 (0)70 305 24 88
E-mail: [email protected]
www.diagonalbio.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
E-mail: [email protected]
About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionizing global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.
